Name

Vipergen

Legal name

Vipergen ApS

Website

https://vipergen.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Drug Discovery Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

akta.pro secondary industry

Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)

Keywords

• DNA-encoded library screening
• Small molecule drug discovery
• Hit identification services
• Molecular glue discovery
• DEL screening technology

Headquarters

HQ city

Copenhagen

HQ country

Denmark

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Fee-For-Service Drug Discovery Services: Vipergen offers straightforward Fee-For-Service arrangements for DEL screening and drug discovery projects. Clients pay for screening services delivered by Vipergen's proprietary technology platforms.
2. Integrated Drug Discovery Partnership: Comprehensive joint ventures and funded discovery partnerships with pharmaceutical and biotechnology companies. Vipergen provides its proprietary suite of DEL technologies through funded discovery partnerships, including top pharmaceutical companies in the USA, EU, and Japan.
3. DEL Series Products: Vipergen launched DEL series products including Lib100 and Lib058 (updated Series 50), offered as part of collaborative arrangements with partners such as Aurigene Pharmaceutical Services Ltd.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Vipergen provides small molecule drug discovery services built on its proprietary DNA-encoded library (DEL) screening platforms: YoctoReactor (yR) for library synthesis, Binder Trap Enrichment (BTE) for in vitro screening, and Cellular Binder Trap Enrichment (cBTE) for screening directly inside living cells. The company delivers hit identification, lead generation, and specialized services such as molecular glue discovery, PPI inhibitor discovery, selectivity profiling, and targeted protein degradation to pharmaceutical and biotechnology clients worldwide. Engagements are structured as Fee-For-Service projects or funded discovery partnerships and joint ventures.

Product overview

Vipergen is a world-leading provider of small molecule drug discovery services based on DNA-encoded library (DEL) technologies. The company offers a platform of three proprietary technologies: YoctoReactor (YR) for high-fidelity library synthesis, Binder Trap Enrichment (BTE) for solution-based in vitro screening, and Cellular Binder Trap Enrichment (cBTE) for screening directly in living cells. Services include DEL screening in both living cells and in vitro formats, with specialized offerings such as Molecular Glue Direct for targeted protein degradation, PPI Inhibitor Direct, Selectivity Direct, Express (fast turnaround), and Snap (affordable option). DEL series products include Lib100 and Lib058. The company provides flexible partnership models from Fee-For-Service to comprehensive joint ventures.

Differentiator

Problem solved

Functional benefit

Brands

• YoctoReactor (yR): Proprietary 2nd-generation library synthesis technology ensuring high fidelity with 100% match between DNA code and compound.
• Binder Trap Enrichment (BTE)
• Cellular Binder Trap Enrichment (cBTE)
• DELs in Cells – Molecular Glue Direct
• DELs in Cells – Express
• DELs in Cells – Snap
• DELs in Cells – PPI Inhibitor Direct

Products and services

• YoctoReactor (yR) Libraries Proprietary 2nd generation library synthesis technology for high-fidelity DNA-encoded library construction with 100% match between DNA code and compound, using designer building blocks for superior chemical diversity.
• Binder Trap Enrichment (BTE) Proprietary 2nd generation screening technology using a solution-based homogeneous assay with no matrix binders and no target denaturation, providing low false positive rates for binder identification.
• Cellular Binder Trap Enrichment (cBTE) Proprietary 3rd generation screening technology that enables DEL screening directly inside living cells without requiring purified target protein, providing physiologically relevant conditions, multiplexing, and broader protein target space.
• DELs in Living Cells Screening DNA-encoded library screening service performed inside living cells using cBTE technology, enabling target screening without purified protein and in physiologically relevant conditions.
• DELs in Vitro Screening DNA-encoded library screening service using BTE technology in a solution-based format for targets that can be purified.
• DELs in Cells - Molecular Glue Direct Direct molecular glue discovery service using multiplexed cBTE screening in living cells with E3 ubiquitin ligases, enabling discovery of molecules that induce POI-E3 ligase interactions for targeted protein degradation.
• DELs in Cells - PPI Inhibitor Direct Service for direct discovery of protein-protein interaction inhibitors using cellular screening format.
• DELs in Cells - Selectivity Direct Multiplexed screening service enabling simultaneous screening of target and anti-targets for selectivity profiling.
• DELs in Cells - Express Fast turnaround-time DEL screening service optimized for rapid hit identification.
• DELs in Cells - Snap Easy, fast, and affordable DEL screening service designed for smaller biotech companies with limited budgets, providing full screening packages with predefined, optimized setup.
• Lib100 DEL Series New DNA-encoded library series product launched as part of Vipergen's strategic partnership with Aurigene Pharmaceutical Services.
• Lib058 DEL Series Updated DNA-encoded library series (renamed from Series 50) launched as part of Vipergen's strategic partnership with Aurigene Pharmaceutical Services.

Quantifiable outcome

• 8-12 weeks from target to hits (vs 6-18 months for traditional HTS)
• +5 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and supporting.

• Aurigene Pharmaceutical Services Ltd.coreStrategic or Co-development Partner · 1 May 2025Strategic partnership to offer DNA encoded library (DEL) screening and integrated drug discovery services to clients. Vipergen launched new DEL series products including Lib100 and Lib058 (updated Series 50) as part of this collaboration. Partnership offers flexible structures ranging from Fee-For-Service arrangements to comprehensive joint ventures.
• SARomics BiostructuressupportingTechnology or IntegrationPartnership page listing on Vipergen's website indicating collaboration in the drug discovery ecosystem. Nature of technical collaboration not fully detailed in available sources.
• Boo Kyung S.M Co.supportingTechnology or IntegrationPartnership page listing on Vipergen's website indicating a collaborative relationship in the drug discovery ecosystem.
• LifeTeinsupportingOthersSupplier of custom peptide and peptide conjugates, listed as part of Vipergen's supplier network.
• BioNordikasupportingOthersSupplier of high-quality reagents and chemicals for molecular biology, protein analysis, and cell-based applications, listed as part of Vipergen's supplier network.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• X-Chem (Evotec): One of the largest dedicated DNA-encoded library (DEL) discovery providers, offering both DEL synthesis and screening services to pharma and biotech — directly comparable to Vipergen's core DEL screening business. Now part of Evotec, giving it substantially greater scale and capital than Vipergen.
• HitGen: Publicly listed DEL-based drug discovery company operating DEL screening, targeted protein degradation (including molecular glues via its subsidiary Vernalis), and partnered discovery programs — overlapping with Vipergen on DEL screening services and molecular glue discovery.
• Philochem: Swiss-based DEL technology and service provider with proprietary DNA-encoded chemistry and screening platforms serving pharma clients — a directly comparable niche DEL services competitor.
• ComInnex: Hungarian DEL technology company offering DNA-encoded library synthesis and screening services to pharma and biotech — closely comparable in scale and service orientation to Vipergen.

Emerging players

• DyNAbind: Emerging DEL platform company with proprietary DNA-encoded chemistry and a focus on challenging drug targets; competing with Vipergen for the same early-discovery service engagements.

Broad incumbents

• WuXi AppTec: Global CRO/CDMO with significant DNA-encoded library and drug discovery service capabilities, serving the same large-pharma customers as Vipergen but at much greater scale and with a far broader service portfolio.
• ChemPartner: Large CRO offering hit identification, medicinal chemistry, and DEL-related services to pharma and biotech — overlapping with Vipergen on drug discovery services, particularly for small biotech and mid-market pharma.
• Evotec: Large contract drug discovery and development organization owning X-Chem (DEL) and offering end-to-end services across target ID through IND — competes with Vipergen both directly via X-Chem's DEL platform and as a broad discovery outsourcing incumbent.

Others

• Aurigene Pharmaceutical Services: Vipergen's 2025 strategic partner for integrated DEL screening and drug discovery services, also operating its own discovery and CDMO offerings — partly a collaboration channel and partly a competitor in integrated drug discovery services.
• Nuevolution (Amgen): Historical DEL competitor (acquired by Amgen in 2019) whose affiliated entity challenged Vipergen's cBTE patent at the EPO in 2026 — represents the in-house DEL capability of a major pharma that also purchases external DEL services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks2 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vipergen